|
1
|
Bérard F, Ferrier Le Bouedec M, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, Milpied B, Pelvet B, Kasujee I, Gharbi H, Lacour J. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase
IV
open‐label
SUNRISE
study. Br J Dermatol 2018; 180:56-66. [DOI: 10.1111/bjd.16904] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2018] [Indexed: 11/30/2022]
Affiliation(s)
- F. Bérard
- Clinical Immunology and Allergology CH Lyon‐Sud Claude Bernard University Lyon I France
| | | | - L. Bouillet
- Department of Internal Medicine Grenoble Alpes University La Tronche France
| | - Z. Reguiai
- Dermatology Department Clinique Courlancy Reims France
| | - A. Barbaud
- Dermatology Department Hospital Tenon Paris France
| | - F. Cambazard
- Dermatology Department CHU Saint‐Etienne Saint‐Etienne France
| | - B. Milpied
- Dermatology Department St. Andre Hospital Bordeaux France
| | - B. Pelvet
- Novartis Pharma SAS Rueil‐Malmaison France
| | | | - H. Gharbi
- Novartis Pharma SAS Rueil‐Malmaison France
| | - J.P. Lacour
- Dermatology Department University Hospital of Nice France
| |
Collapse
|